Evaluation of targeted therapies in patients receiving first-line treatment for metastatic colorectal cancer: cetuximab in the real-life conditions of use

{
"level_sex_clusion_I": [
{
"value": "Male",
"concept": {
"vocab": "MeSH",
"vocabURI": "http:\/\/id.nlm.nih.gov\/mesh\/D008297"
}
},
{
"value": "Female",
"concept": {
"vocab": "MeSH",
"vocabURI": "http:\/\/id.nlm.nih.gov\/mesh\/D005260"
}
}
],
"level_age_clusion_I": [
{
"value": "Young Adult (19 to 24 years)",
"concept": {
"vocab": "MeSH",
"vocabURI": "http:\/\/id.nlm.nih.gov\/mesh\/D055815"
}
},
{
"value": "Adult (25 to 44 years)",
"concept": {
"vocab": "MeSH",
"vocabURI": "http:\/\/id.nlm.nih.gov\/mesh\/D000328"
}
},
{
"value": "Middle Aged (45 to 64 years)",
"concept": {
"vocab": "MeSH",
"vocabURI": "http:\/\/id.nlm.nih.gov\/mesh\/D008875"
}
},
{
"value": "Aged (65 to 79 years)",
"concept": {
"vocab": "MeSH",
"vocabURI": "http:\/\/id.nlm.nih.gov\/mesh\/D000368"
}
},
{
"value": "Aged, 80 and over (80 years and more)",
"concept": {
"vocab": "MeSH",
"vocabURI": "http:\/\/id.nlm.nih.gov\/mesh\/D000369"
}
}
],
"level_type_clusion_I": [
"Patients population"
],
"level_type_clusion_other": "",
"clusion_I": "Patient with metastatic colorectal cancer initiating first-line treatment with cetuximab® between 1 January 2009 and 31 December 2010, whether or not treatment is continued; Patient not previously treated by cetuximab®, including during a clinical trial or Temporary Authorisation for Use; Patient naive to palliative metastatic chemotherapyd; No neoadjuvant chemotherapy \/ adjuvant of primary cancer or interval between the latter and the initiation of first-line treatment with cetuximab® ≥6 months (with a tolerance of 15 days); No neoadjuvant \/ adjuvant of chemotherapy for metastatic cancer between or interval between the latter and initiation of first-line treatment with cetuximab® ≥12 months (with a tolerance of 1 month ); Patient with unresectable metastases immediately before initiation of cetuximab®; Patient with non-mutated K-RAS; Patient not participating in a clinical trial or treatment conditions considered to be unaffected by the coordinating center; Patient without locoregional relapse; Patient not objecting to data collection.",
"clusion_E": ""
}